Avril Biopharma is a full-service biologic contract development manufacturing organization (CDMO) leveraging novel and proprietary technologies to translate medicines (including biologics, vaccines, and gene therapies) from discovery lab to the bedside at low cost. The rational approach to protein design and expression can make the difference between a rapid, low-cost project with definitive results versus a long ambiguous effort of trial and error. When it comes to making a personalized product for one cancer patient, time is everything. We apply our Structural Genetics™ software tools for an integrated use of genomics, molecular biology, and manufacturing quality assurance. Rapid vaccine development for responding to emerging diseases, pandemics or bioterrorism is an area of high focus at the moment. Structural Genetics™ allows epidemiological, clinical and immunogenetic knowledge to be integrated in the design of the best possible vaccine products, while our AdCEV™/Egg manufacturing platform easily scales to any required level – saving lives, money, and time. Avril Biopharma can design and manufacture bespoke, gene-based synthetic biology products. Our nanotechnologies and business model are focused on simplifying manufacturing for nextgeneration medicines so that they are affordable to the widest number of people. We are developing technologies and partnerships to make complex, custom-made, medicines as easily accessible as ordering from the local pharmacy.
SHASHA JUMBE
CHAIRMAN / CEO
Level 42 AI
